These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25631653)

  • 1. Editorial: Call to screen for NAFLD and NASH in psoriasis.
    Verna EC; Loomba R
    Aliment Pharmacol Ther; 2015 Mar; 41(5):492-3. PubMed ID: 25631653
    [No Abstract]   [Full Text] [Related]  

  • 2. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic.
    Roberts KK; Cochet AE; Lamb PB; Brown PJ; Battafarano DF; Brunt EM; Harrison SA
    Aliment Pharmacol Ther; 2015 Feb; 41(3):293-300. PubMed ID: 25521607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis.
    Gisondi P; Barba E; Girolomoni G
    J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):282-7. PubMed ID: 26537011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NASH (non-alcoholic steatohepatitis): fatty liver or fatal liver disease?].
    Roeb E
    Zentralbl Chir; 2014 Apr; 139(2):168-74. PubMed ID: 22441997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study.
    Kocabay G; Karabay CY; Colak Y; Oduncu V; Kalayci A; Akgun T; Guler A; Kirma C
    Clin Sci (Lond); 2014 Feb; 126(4):297-304. PubMed ID: 23947743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?
    Mantovani A; Gisondi P; Lonardo A; Targher G
    Int J Mol Sci; 2016 Feb; 17(2):217. PubMed ID: 26861300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
    Tasneem AA; Luck NH; Majid Z
    Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editors' Introduction to the NAFLD and NASH Special Issue.
    Fuchs M; Schnabl B
    Dig Dis Sci; 2016 May; 61(5):1211-3. PubMed ID: 27068170
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV.
    Rockstroh JK
    Curr HIV/AIDS Rep; 2017 Apr; 14(2):47-53. PubMed ID: 28284005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of MicroRNAs in NAFLD/NASH.
    Szabo G; Csak T
    Dig Dis Sci; 2016 May; 61(5):1314-24. PubMed ID: 26769057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
    Crespo M; Lappe S; Feldstein AE; Alkhouri N
    Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study.
    van der Voort EA; Koehler EM; Dowlatshahi EA; Hofman A; Stricker BH; Janssen HL; Schouten JN; Nijsten T
    J Am Acad Dermatol; 2014 Mar; 70(3):517-24. PubMed ID: 24373781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nonalcoholic fatty liver disease].
    Lemoine M; Serfaty L
    Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.